Business
Notice of Interim Results
Notice of Interim Results.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1562N Angle PLC 27 January 2016 \n\n\n\n\n\nFor Immediate Release\n\n\n27 January 2016\n\n\n\n\n \n \nANGLE plc \n \n(\"ANGLE\" or \"the Company\")\n \nNotice of Interim Results\n \nANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, will announce its interim results for the six months ended 31 October 2015 on Thursday 28 January 2016. \n \nA meeting for analysts will be held at 10:00am on 28 January 2016 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. \n \nTo listen to the live webcast of the analyst meeting, please register at \nhttp://www.angleplc.com/investor-information/corporate-presentations/ for details.\n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nCenkos Securities\nStephen Keys, Dr Christopher Golden (Nominated adviser)\nRussell Kerr, Olly Baxendale (Sales) \n \n\n\n020 7397 8900\n\n\n\n\nFTI Consulting\nSimon Conway, Mo Noonan, Stephanie Cuthbert\nKimberley Ha (US) \n\n\n \n020 3727 1000\n001 212 850 5612\n\n\n\n\n \n \nFor Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/\n \n \nNotes for editors\n \nAbout ANGLE plc www.angleplc.com \n \nANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.\n \nANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in the United States, Canada, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonst...